From July 11 to 13, 2025, the 2025 China Academic Conference on Minimally Invasive Oncology and the 25th Ablation Therapy Conference was successfully held in Beijing. The event was jointly organized by the Beijing Health Promotion Association, the Integrated Interventional Therapy Committee of the Chinese Anti-Cancer Association, the Minimally Invasive Oncology Committee of the Chinese Anti-Cancer Association, and the Interventional Minimally Invasive Therapy Committee of the Chinese Medical Education Association.
Over 200 renowned experts and scholars in the field of minimally invasive tumor treatment from across China gathered in Beijing for this prestigious event. Dr. Niu Lizhi, President of Guangzhou Fuda Cancer Hospital, was invited to attend and present.
On-Site at the Conference
Centered around the themes of Innovation, Intelligence, Integration, and Standardization, the conference featured multiple focused forums and lectures delivered by leading experts in the field.
During the "Combined Thermal and Cryoablation" session, Dr. Niu delivered a keynote presentation titled "Clinical Applications of the Comb-Knife", sharing in-depth insights and real-world clinical outcomes.
Later, at the "NanoKnife Tumor Ablation Session & Hands-On Training Workshop", Dr. Niu presented a series of representative cases involving multi-site tumor ablation using NanoKnife technology, supported by comprehensive clinical data. His presentation was not only rigorous and data-driven but also clear and accessible, earning high praise and recognition from fellow experts.
A significant milestone of this year’s conference was the official establishment of the China IRE (Irreversible Electroporation) Technology Innovation and Promotion Alliance.
Professor Xiao Yueyong from the First Medical Center of the PLA General Hospital was appointed as Chairman of the Alliance, while Dr. Niu Lizhi of Guangzhou Fuda Cancer Hospital was named Vice Chairman.
Dr. Niu remarked that China is now at the forefront globally in terms of both clinical experience and independent development of core equipment in the field of NanoKnife ablation for tumors. As early as July 2015, Fuda Cancer Hospital became the first institution in China to apply this technology to cancer treatment. To date, the hospital has successfully performed over 1,000 NanoKnife procedures.
His election as Vice Chairman not only reflects high-level recognition of Fuda’s achievements in NanoKnife tumor ablation but also serves as a strong motivation for the hospital to continue leading in medical innovation and technical excellence. Dr. Niu pledged to work hand-in-hand with fellow alliance members to promote the wider adoption and development of this cutting-edge technology, ultimately improving patient outcomes and enhancing quality of life.